This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Osprey Medical Restructures Business; Aims to Reduce Credit MT
Osprey Medical, Inc. Announces Board Changes CI
Osprey Medical, Inc. Auditor Raises 'Going Concern' Doubt CI
Osprey Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Transcript : Osprey Medical, Inc., Q4 2021 Earnings Call, Jan 31, 2022
Dyevert Announces Highlighted by Leading Experts for Reduction of Aki CI
Osprey Medical : Fiscal Q1 Global Revenue Jumps 34%; Shares Rise 6% MT
Transcript : Osprey Medical, Inc. - Special Call
Transcript : Osprey Medical, Inc. - Shareholder/Analyst Call
Osprey Medical, Inc. Announces Executive Appointments CI
Osprey Medical, Inc. Announces Earnings Results for the Half Year Ended June 30, 2021 CI
Osprey Medical : Appoints New Board Member MT
Osprey Medical, Inc. Appoints Martin Emerson to its Board of Directors CI
Transcript : Osprey Medical, Inc., Q2 2021 Earnings Call, Jul 29, 2021
Osprey Medical : Expands DyeVert Technology to Canada MT
Osprey Signs an Exclusive Distribution Agreement with GE Healthcare Canada Inc CI
Osprey Medical, Inc. Announces Appointment of Steven Brandt as Director CI
Transcript : Osprey Medical, Inc. - Shareholder/Analyst Call
Transcript : Osprey Medical, Inc., Q1 2021 Earnings Call, Apr 22, 2021
Osprey Medical, Inc. Reports Revenue Results for the First Quarter of 2021 CI
Osprey Medical : Pushes Sales Coverage in US; Shares Jump 5% MT
Osprey Medical, Inc. Sigs Independent Sales Agency Agreements with St Patrick's Distributing Inc CI
Osprey Medical : Expands US Sales Coverage With Three Sales Agreements MT
Osprey Medical, Inc. Signs Independent Sales Agency Agreements with Access Medical Inc., Consolidated Medical Supplies Inc. and Drikot Medical Inc CI
Transcript : Osprey Medical, Inc., Q4 2020 Earnings Call, Jan 28, 2021
Chart OSPY MEDI CDI
More charts
Osprey Medical, Inc. is a commercial stage company, which is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's products include AVERT, AVERT Plus, the DyeVert NG, DyeVert Plus, and DyeVert Plus EZ Systems. The AVERT Plus System reduces and monitors the amount of contrast dye used in commonly performed heart and peripheral vascular procedures. The DyeVert System is a self-adjusting product that reduces the amount of contrast dye used in commonly performed heart and peripheral procedures. DyeVert interfaces with syringe-manifold systems. These technologies are available with the United States Food and Drug Administration cleared indication for dye volume reduction. Its dye reduction and monitoring technologies are designed to help physicians minimize dye usage and reduce kidney damage associated with the use of contrast media for common cardiovascular procedures.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. OSP Stock
  4. News OSPY MEDI CDI
  5. Osprey Medical : Fiscal Q1 Global Revenue Jumps 34%; Shares Rise 6%